Cell and Gene Therapy

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with dermatomyositis. Data has shown that the drug was meant to block TLR 7, 8 and 9 but failed to beat placebo in making a significant change from baseline in the Cutaneous Dermatomyositis Disease Area. Thirty patients took part in the trials for a period of 24 weeks. More than half of the patients were treated with immunosuppressive drugs even then the mean CDASI score was in the severe range. CRISPR might increase cancer risk in edited cells study shows CRISPR-Cas9 always have ...